Susquehanna International Group
KROS icon

Susquehanna International Group’s Keros Therapeutics KROS Stock Holding History

Susquehanna International Group’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$534K Buy
+48,400
New +$747K ﹤0.01% 9489
2025
Q4 		– Sell
-189,200
Closed -$2.99M – 13029
2025
Q3 		$2.99M Sell
189,200
-569,300
-75% -$8.41M ﹤0.01% 4982
2025
Q2 		$10.1M Buy
758,500
+285,400
+60% +$3.85M ﹤0.01% 2815
2025
Q1 		$4.82M Buy
473,100
+427,000
+926% +$4.96M ﹤0.01% 3721
2024
Q4 		$730K Buy
46,100
+42,400
+1,146% +$2.2M ﹤0.01% 7727
2024
Q3 		$215K Buy
+3,700
New +$183K ﹤0.01% 10329
2024
Q2 		– Sell
-5,900
Closed -$391K – 12701
2024
Q1 		$391K Buy
+5,900
New +$350K ﹤0.01% 9084

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Susquehanna International Group's KROS Position: Q1 2026 in Review

Susquehanna International Group reduced its Keros Therapeutics (KROS) stake by 16% in Q1 2026, selling an estimated $33.2K and leaving 11,242 shares worth $124K. The position accounts for ﹤0.01% of the portfolio, ranked #12192.

Susquehanna International Group first reported a position in KROS in Q4 2020 and has held it in 19 quarters since. The position peaked at $3.43M in Q3 2025. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Susquehanna International Group held 11,242 shares of Keros Therapeutics worth $124K as of Q1 2026.
  • Susquehanna International Group sold 2,147 Keros Therapeutics shares in Q1 2026, an estimated $33.2K.
  • Keros Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12192 holding.
  • Susquehanna International Group first reported a position in Keros Therapeutics in Q4 2020 and has held it in 19 quarters since.
  • Susquehanna International Group's Keros Therapeutics position peaked at $3.43M in Q3 2025.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.